Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Controlled, Randomized, Double-Blinded, Within-Subject, Multicenter, Prospective Clinical Study of TEOSYAL® RHA (Resilient Hyaluronic Acid) Ultra Deep Versus Perlane-L® in the Treatment of Moderate to Severe Nasolabial Folds

NCT02253147 is registered in ClinicalTrials.gov with Teoxane SA as lead sponsor.

NCT NCT02253147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02253147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Controlled, Randomized, Double-Blinded, Within-Subject, Multicenter, Prospective Clinical Study of TEOSYAL® RHA (Resilient Hyaluronic Acid) Ultra Deep Versus Perlane-L® in the Treatment of Moderate to Severe Nasolabial Folds
Lead sponsor
Teoxane SA
Phase
Not applicable
Overall status
Completed
Start date
September 30, 2014
Completion date
May 31, 2016
Enrollment
140 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

nasolabial folds, wrinkles